(MedPage Today) — “There is some signal there and we should follow that signal.” — John Carrino, MD, MPH, of Weill Cornell Medicine in New York City, in an FDA advisory committee meeting that supported RP1 (vusolimogene oderparepvec), a twice…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
